UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ⊠ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39522 COMPASS Pathways plc (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State or ...

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights Mar 24, 2026 7:30 AM Eastern Daylight Time Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights Share "COMP360 is shaping the future of mental healthcare, and we are moving the field of psychiatric medicine forward for the millions of people urgently needing better options. As the potential first classic psychedelic approved by the FDA, COMP360 is redefinin ...

Summary of COMPASS Pathways Conference Call Company Overview - **Company**: COMPASS Pathways (NasdaqGS:CMPS) - **Focus**: Development of COMP360 for treatment-resistant depression (TRD) Key Industry Insights - **Market Size**: - Major Depressive Disorder (MDD) affects approximately 23 million patients, with only about 13 million treated with existing FDA-approved products. - TRD specifically affects around 4 million patients, but less than 200,000 are currently treated with TRD-indicated products [12][13]. Core Points and Arguments - **COMP360 Data**: - Recent data indicates that COMP360 has the potential to redefine treatment durability and rapidity in TRD [7]. - A meeting with regulatory agencies is scheduled to discuss a rolling submission and review process for COMP360 [8][9]. - Anticipated completion of the New Drug Application (NDA) submission by late 2026 [9]. - **Regulatory Perspective**: - The FDA is interested in long-term data regarding the efficacy and safety of COMP360, particularly from the COMP006 study [11]. - The focus is on understanding the duration of effects from one or two doses and ensuring no new safety issues arise [11]. - **Commercial Strategy**: - The company aims to ensure broad access to COMP360 upon launch, with a focus on timely rescheduling by the FDA and state authorities [12][14]. - Current efforts are directed towards ensuring that 90% of the patient population is rescheduled within 30 days post-DEA approval [19]. - **Provider Engagement**: - Providers are primarily interested in the availability of psilocybin rather than logistical concerns about administration [22][27]. - COMPASS is working on establishing specific CPT codes for psychedelic treatments to ensure adequate reimbursement for providers [28][32]. - **Patient Population**: - Initial patients are expected to come from high-prescribing Spravato sites, but there is a significant untapped patient population that has not been treated with TRD products [42][43]. - The typical TRD patient has a long history of depression and has failed multiple treatments [47]. Additional Important Insights - **PTSD Research**: - Early data from a small study on PTSD shows promising results, with plans for a larger study underway [50][54]. - The company is confident in the effectiveness of COMP360 for PTSD based on patient narratives and existing research [51]. - **Financial Position**: - Recent financing has provided a runway into 2028, allowing the company to focus on execution and competition with Spravato [57][59]. - **Market Awareness**: - There is significant awareness and interest in COMP360 as the company approaches potential approval [48]. This summary encapsulates the key points discussed during the COMPASS Pathways conference call, highlighting the company's strategic focus, regulatory considerations, and market dynamics surrounding COMP360.

Group 1 - Compass Pathways plc is a biotechnology company focused on improving patient access to evidence-based innovations in mental health [1] - The company will participate in the Stifel 2026 Virtual CNS Forum on March 18, 2026, including a fireside chat at 10:30 AM ET [1] - Compass Pathways is developing COMP360, a synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA for treatment-resistant depression [1] Group 2 - The company announced the exercise of 35,059,448 warrants, generating approximately $200 million in proceeds [1] - Compass Pathways is also attending the TD Cowen 46th Annual Healthcare Conference from March 2-4, 2026, with a fireside chat scheduled for March 3, 2026 [1] - The company priced a public offering of 17,500,000 American Depositary Shares (ADSs) at $8.00 per ADS, raising $150 million [1]

Investment in DraftKings - ARK added approximately 58,048 shares of DraftKings (DKNG) valued at around $1.48 million, with DraftKings holding 1.9% weightage in the ARK Blockchain & Fintech Innovation ETF and 1.05% in the ARK Next Generation Internet ETF [1] - DraftKings benefits from state-by-state legalization across the U.S., expanding its total addressable market, and is focusing on improving profitability through disciplined marketing spending and stronger customer retention metrics [1][5] - DraftKings receives a "Strong Buy" rating on Wall Street, with analysts seeing a potential upside of 45% from current levels if it hits its average price target of $36.41, and a high price target of $53 implies a potential surge of 110.7% over the next year [6] Investment in Robinhood - ARK purchased about 183,933 shares of Robinhood Markets (HOOD) worth roughly $15.12 million, with Robinhood holding 4.3% weightage in the ARK Blockchain & Fintech Innovation ETF and 4.8% in the ARK Next Generation Internet ETF [3] - Robinhood is valued at $69.4 billion and is diversifying its offerings beyond meme-stock trading, including options, retirement accounts, and credit cards [2] - Robinhood receives a "Moderate Buy" rating on Wall Street, with analysts seeing a potential upside of 63% from current levels if it hits its average price target of $125.65, and a high price target of $180 implies a potential surge of 133.5% over the next year [2] Investment in Cerus Corp. - ARK purchased 612,501 shares of Cerus Corp. (CERS) worth about $1.37 million, with Cerus holding 1.2% weightage in the ARK Genomic Revolution ETF and 0.30% in the ARK Innovation ETF [7] - Cerus specializes in pathogen reduction technology for blood safety, with its main product, the INTERCEPT Blood System, helping reduce harmful pathogens in blood components [8] - Cerus stock receives a "Moderate Buy" rating on Wall Street, with analysts seeing a potential upside of 159% from current levels if it hits its average and high price target of $5.00 [9] Investment in Compass Pathways - ARK bought roughly 100,264 shares of Compass Pathways (CMPS) valued at about $706,861, with Compass holding 1.88% in the ARK Genomic Revolution ETF [10] - Compass focuses on creating innovative mental health treatments, particularly COMP360, an investigational psilocybin-based therapy for treatment-resistant depression and PTSD [11] - Compass stock receives a "Strong Buy" rating on Wall Street, with analysts seeing a potential upside of 233% from current levels if it hits its average price target of $21.92, and a high price target of $70 implies a potential surge of 963.8% over the next year [12] Investment in Canton Strategic Holdings - ARK purchased 93,900 shares of Canton Strategic Holdings (CNTN) worth about $439,452, with Canton holding 0.19% weightage in the ARK Blockchain & Fintech Innovation ETF [13] - Canton Strategic Holdings has shifted its focus from a clinical-stage biotech company to managing a digital asset treasury centered on the Canton Network [14] - Small-cap companies like Canton can offer explosive upside if their business models scale successfully, aligning with ARK's strategy of identifying emerging disruptors [15]

COMPASS Pathways (NasdaqGS:CMPS) FY Conference Summary Company Overview - **Company**: COMPASS Pathways - **Ticker**: CMPS - **Focus**: Development of COMP360, a treatment for treatment-resistant depression (TRD) Key Highlights from Phase III Studies Study Designs - **Study 005**: Placebo-controlled, 25 mg COMP360 vs. placebo, 6-week primary endpoint measuring change in MADRS (Montgomery-Åsberg Depression Rating Scale) from baseline after a single administration - **Study 006**: Three arms (10 mg, 25 mg, and 1 mg psilocybin), with two initial administrations three weeks apart, also with a 6-week primary endpoint [2][4] Results - **Study 005**: - 3.6 point difference in MADRS at primary endpoint, statistically significant at all time points [3] - 40% of patients receiving a second administration achieved remission [4] - **Study 006**: - 3.8 point difference between 25 mg and 1 mg active comparator at week 6, statistically significant at all time points [4] Clinical Significance - A clinically meaningful benefit is defined as at least a 25% reduction in MADRS, with 25% of patients in Study 005 and nearly 40% in Study 006 achieving this [9] Incremental Benefits of Dosing - The second dose may provide nuanced benefits, potentially increasing remission rates rather than just mean population MADRS separation [5][6] - The consistency of results across multiple trials suggests a durable response to treatment [21][22] Patient Quality of Life - A 25% reduction in MADRS correlates to significant improvements in daily functioning and quality of life for TRD patients [26][31] Commercial Strategy - The 10 mg dose did not meet clinical relevance at six weeks, but is being explored in PTSD trials [62][65] - The 25 mg dose is the primary focus for launch due to its robust statistical significance [62] FDA Relationship and Regulatory Strategy - The company maintains a strong relationship with the FDA, emphasizing a thorough and robust development process for COMP360 [83][84] - The FDA has encouraged the submission of data on a rolling basis, which may expedite the approval process [88] Safety and Monitoring - The safety profile of COMP360 is favorable, with a low barrier for patients to try the treatment [112] - The treatment model aligns with existing psychiatric care frameworks, utilizing similar facilities and personnel as current treatments like SPRAVATO [124][125] Future Data and Analysis - Additional data on quality of life outcomes and secondary metrics will be analyzed and reported in upcoming conferences [72][73] - Real-world evidence post-approval will help refine patient profiles for predicting treatment response [105][106] Conclusion - COMPASS Pathways is positioned to potentially revolutionize treatment for TRD with COMP360, supported by promising clinical data and a proactive regulatory strategy. The focus on patient quality of life and safety further enhances its commercial viability.

Core Viewpoint - Compass Pathways plc is focused on enhancing patient access to evidence-based innovations in mental health and will participate in the TD Cowen 46th Annual Healthcare Conference in March 2026 [1] Company Participation - Management will attend the conference in Boston, MA, from March 2-4, 2026 [1] - A fireside chat is scheduled for March 3, 2026, at 10:30 am ET [1] - A live audio webcast of the event will be available on the company's Investors section [1]

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Viewpoint - Compass Pathways plc has announced the pricing of its public offering, aiming to enhance patient access to innovative treatments [1] Group 1: Public Offering Details - The company is offering 17,500,000 American Depositary Shares (ADSs) at a price of $8.00 per ADS, with each ADS representing one ordinary share [1] - Additionally, the company is providing pre-funded warrants to certain institutional investors to purchase up to 1,250,000 ADSs at a price of $7.9999 [1]

Group 1 - The webinar is hosted by Stephen Schultz, Senior Vice President of Investor Relations for COMPASS Pathways [2] - The call is being recorded, indicating a formal update on the company's status [1] - Forward-looking statements will be made during the call, which are subject to risks and uncertainties [3]